Day One Biopharmaceuticals (DAWN) has shared an announcement.
Day One Biopharmaceuticals, Inc. has struck an exclusive deal with Ipsen Pharma SAS to license the commercialization rights of their drug tovorafenib outside the U.S. In return, Day One will receive an upfront payment of $71 million, a $40 million equity investment at a premium price, and could earn up to an additional $350 million in milestone payments plus royalties. The agreement, which allows for termination under specific conditions, will be detailed in Day One’s upcoming quarterly report and was announced in a recent press release.
For an in-depth examination of DAWN stock, go to TipRanks’ Stock Analysis page.
